Treatment.Com International Inc.

As of June 30, 2025, Treatment.Com International Inc. has 75.50M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 42.08, and the price-to-book ratio stands at -5.26.

These figures are as of June 30, 2025. The EV/Sales ratio of 43.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2025, Treatment.Com International Inc. maintains a current ratio of 0.09, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.58, indicating elevated leverage, while an interest coverage ratio of -458.79 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -89.39, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2025, Treatment.Com International Inc. posted a gross margin of 89.39, reflecting its pricing power and cost economics. The operating margin of -1,585.60 and net profit margin of -1,670.11 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Free cash flow yield is negative at -23.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.39, meaning Treatment.Com International Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Treatment.Com International Inc.'s most recent stock split took place on July 14, 2023 with a 10:1 split ratio.

As of June 30, 2025, Treatment.Com International Inc. has an Altman Z-Score of -138.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.